1.36
price down icon2.23%   -0.02
 
loading
Precedente Chiudi:
$1.38
Aprire:
$1.35
Volume 24 ore:
67,387
Relative Volume:
0.46
Capitalizzazione di mercato:
$49.74M
Reddito:
-
Utile/perdita netta:
$-9.16M
Rapporto P/E:
-2.386
EPS:
-0.57
Flusso di cassa netto:
$-8.75M
1 W Prestazione:
+2.99%
1M Prestazione:
+13.38%
6M Prestazione:
+6.24%
1 anno Prestazione:
+22.65%
Intervallo 1D:
Value
$1.33
$1.37
Intervallo di 1 settimana:
Value
$1.31
$1.40
Portata 52W:
Value
$0.75
$1.6899

Renovorx Inc Stock (RNXT) Company Profile

Name
Nome
Renovorx Inc
Name
Telefono
408-800-2649
Name
Indirizzo
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Name
Dipendente
10
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-15
Name
Ultimi documenti SEC
Name
RNXT's Discussions on Twitter

Confronta RNXT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RNXT
Renovorx Inc
1.36 49.74M 0 -9.16M -8.75M -0.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.32 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
510.83 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
310.31 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
537.22 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.00 28.51B 3.81B -644.79M -669.77M -6.24

Renovorx Inc Borsa (RNXT) Ultime notizie

pulisher
Jun 16, 2025

Short Interest in RenovoRx, Inc. (NASDAQ:RNXT) Declines By 35.4% - Defense World

Jun 16, 2025
pulisher
Jun 12, 2025

Citadel Advisors LLC Invests $49,000 in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

RenovoRX chief medical officer buys $29,399 in common stock By Investing.com - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

RenovoRX chief medical officer buys $29,399 in common stock - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Insider Buying: Ramtin Agah Acquires Additional Shares of RenovoRx Inc (RNXT) - GuruFocus

Jun 09, 2025
pulisher
Jun 08, 2025

RenovoRx (NASDAQ:RNXT) Stock Rating Upgraded by Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

RenovoRx (NASDAQ:RNXT) Given New $11.50 Price Target at Ascendiant Capital Markets - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results - Yahoo Finance

Jun 06, 2025
pulisher
Jun 05, 2025

Ascendiant Capital raises RenovoRx stock price target to $11.50 By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

RenovoRx (RNXT) Price Target Increased by Ascendiant Analyst | R - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

RenovoRx (RNXT) Price Target Increased by Ascendiant Analyst | RNXT Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

RenovoRx (RNXT) Price Target Raised to $11.50 by Ascendiant Capi - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ascendiant Capital raises RenovoRx stock price target to $11.50 - Investing.com

Jun 05, 2025
pulisher
May 29, 2025

New U.S. Patent Issued to RenovoRx for Drug Therapy Platform - Medical Product Outsourcing

May 29, 2025
pulisher
May 26, 2025

RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment - simplywall.st

May 26, 2025
pulisher
May 22, 2025

Q2 Earnings Forecast for RenovoRx Issued By HC Wainwright - Defense World

May 22, 2025
pulisher
May 21, 2025

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 21, 2025
pulisher
May 20, 2025

RenovoRx (NASDAQ:RNXT) Receives “Buy” Rating from HC Wainwright - Defense World

May 20, 2025
pulisher
May 20, 2025

RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook - TipRanks

May 20, 2025
pulisher
May 19, 2025

RenovoRx (RNXT): HC Wainwright Reiterates Buy Rating with $3.00 Target | RNXT Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript - MSN

May 18, 2025
pulisher
May 17, 2025

RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating - TipRanks

May 17, 2025
pulisher
May 16, 2025

RenovoRx Earnings Call: Positive Outlook Amid Growth - TipRanks

May 16, 2025
pulisher
May 16, 2025

RenovoRx Inc (RNXT) Q1 2025 Earnings: EPS of -$0.08 Beats Estima - GuruFocus

May 16, 2025
pulisher
May 16, 2025

RenovoRx earnings beat, revenue fell short of estimates - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

RenovoRx Reports Promising Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 15, 2025

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations - Investing.com

May 15, 2025
pulisher
May 15, 2025

RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace

May 15, 2025
pulisher
May 15, 2025

RenovoRx Q1 2025 Earnings Call Transcript - MarketBeat

May 15, 2025
pulisher
May 15, 2025

RenovoRx reports Q1 EPS (8c), consensus (8c) - TipRanks

May 15, 2025
pulisher
May 15, 2025

RenovoRx (RNXT) Reports Strong Q1 Revenue Surpassing Expectations | RNXT Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

RenovoRx Reports Strong Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - BioSpace

May 14, 2025
pulisher
May 08, 2025

RenovoRx Expands RenovoCath Production to Meet an Increasing Demand - Zenopa

May 08, 2025
pulisher
May 08, 2025

Renaissance Technologies LLC Makes New Investment in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World

May 08, 2025
pulisher
May 06, 2025

RenovoRx Ramps Up U.S. Production of RenovoCath Devices - Medical Product Outsourcing

May 06, 2025
pulisher
May 06, 2025

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform - Business Wire

May 06, 2025
pulisher
May 02, 2025

RenovoRx (RNXT) Projected to Post Earnings on Friday - Defense World

May 02, 2025
pulisher
May 01, 2025

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET - BioSpace

May 01, 2025
pulisher
Apr 30, 2025

CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer - Curetoday

Apr 30, 2025
pulisher
Apr 30, 2025

Ascendiant Capital Markets Forecasts Strong Price Appreciation for RenovoRx (NASDAQ:RNXT) Stock - The AM Reporter

Apr 30, 2025
pulisher
Apr 29, 2025

RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer T - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer Treatment | RNXT Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx'S Ongoing Phase III Tiger-Pac Clinical Trial - marketscreener.com

Apr 29, 2025

Renovorx Inc Azioni (RNXT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Renovorx Inc Azioni (RNXT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Marton Laurence
Director
May 02 '25
Option Exercise
0.15
20,480
3,072
66,164
Agah Ramtin
Chief Medical Officer
Apr 15 '25
Buy
0.90
15,000
13,500
1,113,460
Bagai Shaun
Chief Executive Officer
Apr 15 '25
Buy
0.91
7,500
6,821
320,040
Agah Ramtin
Chief Medical Officer
Apr 11 '25
Buy
0.80
20,000
16,000
1,098,460
Kocak Ron
VP Controller and PAO
Apr 10 '25
Buy
0.79
6,500
5,135
12,595
Kocak Ron
VP Controller and PAO
Apr 09 '25
Buy
0.80
6,000
4,800
6,095
Kocak Ron
VP Controller and PAO
Apr 08 '25
Buy
0.80
95
76
95
Agah Ramtin
Chief Medical Officer
Apr 09 '25
Buy
0.81
30,000
24,399
1,078,460
Bagai Shaun
Chief Executive Officer
Apr 09 '25
Buy
0.83
10,000
8,300
312,540
Marton Laurence
Director
Apr 08 '25
Buy
0.85
12,050
10,218
45,684
$20.89
price down icon 0.66%
$35.12
price up icon 1.05%
$20.60
price up icon 1.48%
$102.01
price down icon 1.01%
$105.16
price down icon 1.24%
biotechnology ONC
$258.31
price up icon 6.02%
Capitalizzazione:     |  Volume (24 ore):